Asthma is a chronic inflammatory disease of the airways that is challenging to dissect into
subgroups because of the heterogeneity present across the spectrum of the disease. Efforts …

Five biological drugs are currently marketed for treatment of uncontrolled severe asthma.
They all block type 2 inflammatory pathways by targeting IgE (omalizumab), the IL-5 …

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA).
The aim of the STELLAIR study was to determine the importance of pre-treatment blood …

Background Benralizumab is an IL-5Rα–directed monoclonal antibody indicated for patients
with severe, uncontrolled eosinophilic asthma. Objective To evaluate the long-term safety …

Introduction Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was
demonstrated in randomised controlled trials; data on its real-world impact in routine clinical …

Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic
asthma are not well characterized in global, real-life severe asthma cohorts. Research …

Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of
constant research because it greatly affects patients' quality of life, and patients with severe …

Severe asthma is “asthma which requires treatment with high dose inhaled corticosteroids
(ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming …

Background With the introduction of different targeted therapies for type 2 (T2)-high asthma,
there is an urgent need for markers to guide the choice of treatment. T2-high asthma …

Severe asthma is a heterogeneous disease with different phenotypes based on clinical,
functional or inflammatory parameters. In particular, the eosinophilic phenotype is …